Skin and Mucous Membrane Agents
### SKIN AND MUCOUS MEMBRANE AGENTS

#### COMPOUND PRESCRIPTION

<table>
<thead>
<tr>
<th>Compound Type</th>
<th>Compound Description</th>
<th>Unit</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOPICAL</td>
<td>COMPOUND - RETINOIC ACID (TRETINOIN) (TOPICAL)</td>
<td>XXX</td>
<td>$0.0000</td>
</tr>
<tr>
<td>TOPICAL</td>
<td>MISCELLANEOUS TOPICAL COMPOUND</td>
<td>XXX</td>
<td>$0.0000</td>
</tr>
</tbody>
</table>

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

<table>
<thead>
<tr>
<th>Compound Type</th>
<th>Compound Description</th>
<th>Unit</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOPICAL</td>
<td>COMPOUND - RETINOIC ACID (TRETINOIN) (TOPICAL)</td>
<td>XXX</td>
<td>$0.0000</td>
</tr>
<tr>
<td>TOPICAL</td>
<td>MISCELLANEOUS TOPICAL COMPOUND</td>
<td>XXX</td>
<td>$0.0000</td>
</tr>
</tbody>
</table>

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
SKIN AND MUCOUS MEMBRANE AGENTS

ANTI-INFECTIVES

COMPOUND PRESCRIPTION
TOPOCAL

00000999103  COMPOUND-ANTI-INFECTIVE (TOPICAL)  XXX  $  0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

TOPOCAL

00000999203  COMPOUND-ANTI-INFECTIVE (TOPICAL)  XXX  $  0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.
### ALBERTA DRUG BENEFIT LIST

#### 84:00 SKIN AND MUCOUS MEMBRANE AGENTS

#### 84:04.04 ANTI-INFECTIVES

**ANTIFUNGALS**

### (ALLYLAMINES)

#### TERBINAFINE HCL

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand</th>
<th>Manufacturer</th>
<th>Unit Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% topical cream</td>
<td>Lamisil</td>
<td>NOV</td>
<td>$0.5456</td>
</tr>
<tr>
<td>1% topical solution</td>
<td>Lamisil</td>
<td>NOV</td>
<td>$0.5543</td>
</tr>
</tbody>
</table>

#### 84:00 SKIN AND MUCOUS MEMBRANE AGENTS

#### 84:04.08 ANTI-INFECTIVES

**ANTIFUNGALS**

### (AZOLES)

#### KETOCONAZOLE

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand</th>
<th>Manufacturer</th>
<th>Unit Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>2% topical cream</td>
<td>Ketoderm</td>
<td>TPT</td>
<td>$0.3888</td>
</tr>
</tbody>
</table>

---

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

UNIT OF ISSUE - REFER TO PRICE POLICY 189  EFFECTIVE APRIL 1, 2018
84:00 SKIN AND MUCOUS MEMBRANE AGENTS
84:04.08.20 ANTI-INFECTIVES
ANTIFUNGALS
(HYDROXYPYRIDONES)

CICLOPIROX OLAMINE
1 % TOPICAL CREAM
00002221802 LOPROX VCL $ 0.3128

84:00 SKIN AND MUCOUS MEMBRANE AGENTS
84:04.92 ANTI-INFECTIVES
(MISCELLANEOUS LOCAL ANTI-INFECTIVES)

SILVER SULFADIAZINE
1 % TOPICAL CREAM
00000323098 FLAMAZINE SNE $ 0.2048

84:00 SKIN AND MUCOUS MEMBRANE AGENTS
84:06 ANTI-INFLAMMATORY AGENTS

AMCINONIDE
0.1 % TOPICAL CREAM
0002246714 TARO-AMCINONIDE TAR $ 0.2146
0002192284 CYCLOCORT GSK $ 0.2500

BECLOMETHASONE DIPROPIONATE
250 MCG / G TOPICAL CREAM
0002089602 PROPADERM VCL $ 0.4553

BETAMETHASONE DIPROPIONATE
0.05 % (BASE) TOPICAL CREAM
0000804991 RATIO-TOPISONE TEV $ 0.2046
0000323071 DIPROSONE MFC $ 0.2091
0.05 % (BASE) TOPICAL GLYCOL CREAM
0000688622 DIPROLENE GLYCOL MFC $ 0.5186
0000849650 RATIO-TOPILENE TEV $ 0.5186
0.05 % (BASE) TOPICAL OINTMENT
0000805009 RATIO-TOPISONE TEV $ 0.2152
0000344923 DIPROSONE MFC $ 0.2197
0.05 % (BASE) TOPICAL GLYCOL OINTMENT
0000629367 DIPROLENE GLYCOL MFC $ 0.5186
0000849669 RATIO-TOPILENE TEV $ 0.5186
0.05 % (BASE) TOPICAL LOTION
0000809187 RATIO-TOPISONE TEV $ 0.1980
0000417246 DIPROSONE MFC $ 0.2022
0.05 % (BASE) TOPICAL GLYCOL LOTION
0001927914 RATIO-TOPISALIC TEV $ 0.2697

BETAMETHASONE DIPROPIONATE/ SALICYLIC ACID
0.5 MG / G (BASE) * 30 MG / G TOPICAL OINTMENT
0000578436 DIPROSALIC MFC $ 0.9084
0.5 MG / ML (BASE) * 20 MG / ML TOPICAL LOTION
0002245688 RATIO-TOPISALIC TEV $ 0.4364
0000578428 DIPROSALIC MFC $ 0.4512

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

PRODUCT IS NOT INTERCHANGEABLE 190 EFFECTIVE APRIL 1, 2018
## ALBERTA DRUG BENEFIT LIST

### 84:00 SKIN AND MUCOUS MEMBRANE AGENTS

### 84:06 ANTI-INFLAMMATORY AGENTS

#### BETAMETHASONE SODIUM PHOSPHATE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 MG / ENM (BASE)</td>
<td>RECTAL ENEMA</td>
<td>BETNESOL (5MG/100ML)</td>
</tr>
<tr>
<td>0.05 % (BASE)</td>
<td>TOPICAL CREAM</td>
<td>BETNESOL (5MG/100ML)</td>
</tr>
</tbody>
</table>

#### BETAMETHASONE VALERATE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 % (BASE)</td>
<td>TOPICAL CREAM</td>
<td>BETADERM MILD</td>
</tr>
<tr>
<td>0.05 % (BASE)</td>
<td>TOPICAL OINTMENT</td>
<td>BETADERM REGULAR</td>
</tr>
<tr>
<td>0.05 % (BASE)</td>
<td>TOPICAL LOTION</td>
<td>BETADERM REGULAR</td>
</tr>
<tr>
<td>0.05 % (BASE)</td>
<td>SCALP LOTION</td>
<td>BETADERM MILD</td>
</tr>
</tbody>
</table>

#### BUDESONIDE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3 MG / ENM</td>
<td>RECTAL ENEMA</td>
<td>ENTOCORT (115 ML)</td>
</tr>
</tbody>
</table>

#### CLOBETASOL 17-PROPIONATE

<table>
<thead>
<tr>
<th>Strength</th>
<th>Formulation</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 %</td>
<td>TOPICAL CREAM</td>
<td>MYLAN-CLOBETASOL</td>
</tr>
<tr>
<td>0.05 %</td>
<td>TOPICAL OINTMENT</td>
<td>MYLAN-CLOBETASOL</td>
</tr>
<tr>
<td>0.05 %</td>
<td>SCALP LOTION</td>
<td>MYLAN-CLOBETASOL</td>
</tr>
</tbody>
</table>

---

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**UNIT OF ISSUE - REFER TO PRICE POLICY**

**191**

**EFFECTIVE APRIL 1, 2018**
SKIN AND MUCOUS MEMBRANE AGENTS

ANTI-INFLAMMATORY AGENTS

COMPOUND PRESCRIPTION

TOPOCAL

00000999107    COMPOUND-CORTICOSTEROIDS - TOPICAL XXX    $  0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

TOPOCAL

00000999207    COMPOUND-CORTICOSTEROIDS - TOPICAL XXX    $  0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

DESONIDE

0.05 %    TOPICAL CREAM

00002229315    PDP-DESONIDE    PPH    $  0.3757

0.05 %    TOPICAL OINTMENT

00002229323    PDP-DESONIDE    PPH    $  0.3564
# ALBERTA DRUG BENEFIT LIST

## 84:00 SKIN AND MUCOUS MEMBRANE AGENTS

### 84:06 ANTI-INFLAMMATORY AGENTS

**DESOXIMETASONE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>VCL</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05% topical cream</td>
<td>TOPICORT MILD</td>
<td>VCL</td>
<td>$0.5039</td>
</tr>
<tr>
<td>0.25% topical cream</td>
<td>TOPICORT</td>
<td>VCL</td>
<td>$0.7126</td>
</tr>
</tbody>
</table>

**FLUOCINONIDE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>VCL</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05% topical cream</td>
<td>LIDEX</td>
<td>VCL</td>
<td>$0.2497</td>
</tr>
<tr>
<td>0.05% topical cream</td>
<td>LYDERM</td>
<td>TPT</td>
<td>$0.2498</td>
</tr>
<tr>
<td>0.05% topical emollient cream</td>
<td>LIDEMOL</td>
<td>VCL</td>
<td>$0.2079</td>
</tr>
<tr>
<td>0.05% topical ointment</td>
<td>LYDERM</td>
<td>TPT</td>
<td>$0.3122</td>
</tr>
<tr>
<td>0.05% topical gel</td>
<td>LYDERM</td>
<td>VCL</td>
<td>$0.3153</td>
</tr>
</tbody>
</table>

**HALOBETASOL PROPIONATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>VCL</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05% topical cream</td>
<td>ULTRAVATE</td>
<td>VCL</td>
<td>$0.9569</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>VCL</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% topical cream</td>
<td>EMO-CORT</td>
<td>GSK</td>
<td>$0.1718</td>
</tr>
<tr>
<td>1% topical occlusive cream</td>
<td>PREVEX HC</td>
<td>GSK</td>
<td>$0.2703</td>
</tr>
<tr>
<td>0.5% topical ointment</td>
<td>CORTODERM MILD</td>
<td>TAR</td>
<td>$0.1667</td>
</tr>
<tr>
<td>1% topical ointment</td>
<td>CORTODERM REGULAR</td>
<td>TAR</td>
<td>$0.0516</td>
</tr>
<tr>
<td>1% topical lotion</td>
<td>JAMP-HYDROCORTISONE</td>
<td>JPC</td>
<td>$0.1191</td>
</tr>
<tr>
<td>100 mg / enm rectal enema</td>
<td>CORTENEMA (100MG/60ML)</td>
<td>AXC</td>
<td>$7.2841</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE 17-VALERATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>TPT</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2% topical cream</td>
<td>HYDROVAL</td>
<td>TPT</td>
<td>$0.1667</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE ACETATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand Name</th>
<th>TAR</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5% topical cream</td>
<td>HYDERM</td>
<td>TAR</td>
<td>$0.1909</td>
</tr>
<tr>
<td>1% topical cream</td>
<td>HYDERM</td>
<td>TAR</td>
<td>$0.0508</td>
</tr>
<tr>
<td>1% topical cream</td>
<td>DERMAFLEX HC</td>
<td>PAL</td>
<td>$0.1790</td>
</tr>
<tr>
<td>1% topical lotion</td>
<td>DERMAFLEX HC</td>
<td>PAL</td>
<td>$0.1007</td>
</tr>
<tr>
<td>10% rectal foam</td>
<td>CORTIFOM</td>
<td>PAL</td>
<td>$6.6733</td>
</tr>
</tbody>
</table>

---

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**UNIT OF ISSUE - REFER TO PRICE POLICY**

**193**

**EFFECTIVE APRIL 1, 2018**
### 84:00 SKIN AND MUCOUS MEMBRANE AGENTS

#### 84:06 ANTI-INFLAMMATORY AGENTS

**HYDROCORTISONE ACETATE/ PRAMOXINE HCL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Product Code</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% * 1% Rectal Foam</td>
<td>0000363014</td>
<td>PROCTOFOAM-HC</td>
<td>$1.3839</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE ACETATE/ PRAMOXINE HCL/ ZINC SULFATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Product Code</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg * 20 mg * 10 mg Rectal Suppository</td>
<td>00002240851</td>
<td>PROCTODAN-HC</td>
<td>$0.7825</td>
</tr>
<tr>
<td></td>
<td>00002242797</td>
<td>SANDOZ ANUZINC HC PLUS</td>
<td>$0.7825</td>
</tr>
<tr>
<td></td>
<td>00000476242</td>
<td>ANUGESIC-HC</td>
<td>$1.3650</td>
</tr>
<tr>
<td>0.5% * 1% * 0.5% Rectal Ointment</td>
<td>00002234466</td>
<td>PROCTODAN-HC</td>
<td>$0.7314</td>
</tr>
<tr>
<td></td>
<td>00000505781</td>
<td>ANUGESIC-HC</td>
<td>$0.9100</td>
</tr>
</tbody>
</table>

**HYDROCORTISONE ACETATE/ ZINC SULFATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Product Code</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg * 10 mg Rectal Suppository</td>
<td>00002236399</td>
<td>ANODAN-HC</td>
<td>$0.5833</td>
</tr>
<tr>
<td></td>
<td>00002242798</td>
<td>SANDOZ ANUZINC HC</td>
<td>$0.5833</td>
</tr>
<tr>
<td></td>
<td>00000476285</td>
<td>ANUSOL-HC</td>
<td>$1.1183</td>
</tr>
<tr>
<td>0.5% * 0.5% Rectal Ointment</td>
<td>00002128446</td>
<td>ANODAN-HC</td>
<td>$0.3850</td>
</tr>
<tr>
<td></td>
<td>00002387239</td>
<td>JAMPZINC-HC</td>
<td>$0.3850</td>
</tr>
<tr>
<td></td>
<td>00002247691</td>
<td>SANDOZ ANUZINC HC</td>
<td>$0.3850</td>
</tr>
<tr>
<td></td>
<td>00000505773</td>
<td>ANUSOL-HC</td>
<td>$0.7827</td>
</tr>
</tbody>
</table>

**MOMETASONE FUROATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Product Code</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1% Topical Cream</td>
<td>00002367157</td>
<td>TARO-MOMETASONE</td>
<td>$0.5708</td>
</tr>
<tr>
<td></td>
<td>00000851744</td>
<td>ELOCOM</td>
<td>$0.7098</td>
</tr>
<tr>
<td>0.1% Topical Ointment</td>
<td>00002248130</td>
<td>RATIO-MOMETASONE</td>
<td>$0.6013</td>
</tr>
<tr>
<td></td>
<td>00000851736</td>
<td>ELOCOM</td>
<td>$0.6384</td>
</tr>
<tr>
<td>0.1% Topical Lotion</td>
<td>00002266385</td>
<td>TARO-MOMETASONE</td>
<td>$0.3788</td>
</tr>
<tr>
<td></td>
<td>00000871095</td>
<td>ELOCOM</td>
<td>$0.4759</td>
</tr>
</tbody>
</table>

**TRIAMCINOLONE ACETONIDE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Product Code</th>
<th>Brand</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1% Topical Cream</td>
<td>00000716960</td>
<td>TRIADERM REGULAR</td>
<td>$0.1024</td>
</tr>
<tr>
<td></td>
<td>00002194058</td>
<td>ARISTOCORT R</td>
<td>$0.1368</td>
</tr>
<tr>
<td>0.5% Topical Cream</td>
<td>00002194066</td>
<td>ARISTOCORT C</td>
<td>$1.2139</td>
</tr>
<tr>
<td>0.1% Topical Ointment</td>
<td>00002194031</td>
<td>ARISTOCORT R</td>
<td>$0.1386</td>
</tr>
<tr>
<td>0.1% Dental Paste</td>
<td>00001964054</td>
<td>ORACORT</td>
<td>$1.4623</td>
</tr>
</tbody>
</table>

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
**84:00 SKIN AND MUCOUS MEMBRANE AGENTS**

84:06.00 ANTI-INFLAMMATORY AGENTS

(COMBINATION ANTI-INFECTIVE/ANTI-INFLAMMATORY AGENTS)

<table>
<thead>
<tr>
<th>BETAMETHASONE DIPROPIONATE/ CLOTRIMAZOLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 % (BASE) * 1 % TOPICAL CREAM</td>
</tr>
<tr>
<td>00000611174</td>
</tr>
<tr>
<td>LOTRIDERM</td>
</tr>
<tr>
<td>MFC</td>
</tr>
<tr>
<td>$ 0.7916</td>
</tr>
</tbody>
</table>

**COMPOUND PRESCRIPTION**

<table>
<thead>
<tr>
<th>00000999110</th>
<th>COMBINATION ANTI-INFECTIVE/CORTICOSTEROID</th>
<th>XXX</th>
<th>$ 0.0000</th>
</tr>
</thead>
</table>

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

<table>
<thead>
<tr>
<th>00000999211</th>
<th>COMBINATION ANTI-INFECTIVE/CORTICOSTEROID</th>
<th>XXX</th>
<th>$ 0.0000</th>
</tr>
</thead>
</table>

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
### SKIN AND MUCOUS MEMBRANE AGENTS

#### 84:00  SKIN AND MUCOUS MEMBRANE AGENTS

#### 84:06.00  ANTI-INFLAMMATORY AGENTS

**(COMBINATION ANTI-INFECTIVE/ANTI-INFLAMMATORY AGENTS)**

**HYDROCORTISONE/ CINCHOCAINE HCL/ FRAMYCETIN SULFATE/ ESCULIN**

- **5 MG * 5 MG * 10 MG * 10 MG** **RECTAL** **SUPPOSITORY**
  - 00002247882  PROCTOL  ODN  $ 0.6000
  - 00002226391  RATIO-PROCTOSONE  TEV  $ 0.6000
  - 00002242528  SANDOZ PROCTOMYXIN HC  SDZ  $ 0.6000

- **5 MG / G * 5 MG / G * 10 MG / G * 10 MG / G** **RECTAL** **OINTMENT**
  - 00002247322  PROCTOL  ODN  $ 0.4000
  - 00002226383  RATIO-PROCTOSONE  TEV  $ 0.4000
  - 00002242527  SANDOZ PROCTOMYXIN HC  SDZ  $ 0.4000
  - 00002223252  PROCTOSEDYL  AXC  $ 0.8450

#### 84:08  ANTI-PRURITICS AND LOCAL ANESTHETICS

**LIDOCAINE**

- **5 %** **TOPICAL** **OINTMENT**
  - 00002083795  LIDODAN  ODN  $ 0.2800
  - 00000001961  XYLOCAINE  APC  $ 0.3171

**LIDOCAINE HCL**

- **2 %** **TOPICAL** **JELLY**
  - ☒ 00002143879  LIDODAN  ODN  $ 0.3625
  - ☒ 00000001694  XYLOCAINE JELLY  APC  $ 0.5150

---

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
SKIN AND MUCOUS MEMBRANE AGENTS

KERATOLYTIC AGENTS

COMPOUND PRESCRIPTION

TOPOCAL

00000999104 COMPOUND- SALICYLIC ACID (TOPOCAL) XXX $ 0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

TOPOCAL

00000999204 COMPOUND- SALICYLIC ACID (TOPOCAL) XXX $ 0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and

- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and

- the compounded prescription must not include a chemical entity or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

SKIN AND MUCOUS MEMBRANE AGENTS

MISCELLANEOUS SKIN AND MUCOUS MEMBRANE AGENTS

5-FLUOROURACIL

50 MG / G TOPOCAL CREAM

00000330582 EFUDEX VCL $ 0.8852

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.
### Skin and Mucous Membrane Agents

#### Acitretin
- **10 mg Oral Capsule**
  - Product Code: 00002070847
  - Prescribing Code: ACV
  - Price: $2.2528
- **25 mg Oral Capsule**
  - Product Code: 00002070863
  - Prescribing Code: ACV
  - Price: $3.9561

#### Azelaic Acid
- **15% topical gel**
  - Product Code: 00002270811
  - Prescribing Code: BAI
  - Price: $0.6066

#### Calcipotriol
- **50 mcg/g topical ointment**
  - Product Code: 00001976133
  - Prescribing Code: LEO
  - Price: $0.7679

#### Calcipotriol Monohydrate/Betamethasone Dipropionate
- **50 mcg/g (base) * 0.5 mg/g (base) topical ointment**
  - Product Code: 00002244126
  - Prescribing Code: LEO
  - Price: $1.5165
- **50 mcg/g (base) * 0.5 mg/g (base) topical gel**
  - Product Code: 00002319012
  - Prescribing Code: LEO
  - Price: $1.4854

#### Collagenase
- **250 unit/g topical ointment**
  - Product Code: 00002063670
  - Prescribing Code: SNE
  - Price: $3.0330

#### Isotretinoin
- **10 mg Oral Capsule**
  - Product Code: 00002257955
  - Prescribing Code: MYP
  - Price: $0.9313
- **40 mg Oral Capsule**
  - Product Code: 00002257963
  - Prescribing Code: MYP
  - Price: $1.9003

#### Tazarotene
- **0.05% topical gel**
  - Product Code: 00002230784
  - Prescribing Code: ALL
  - Price: $1.3886
- **0.1% topical gel**
  - Product Code: 00002230785
  - Prescribing Code: ALL
  - Price: $1.3886

---

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.